Nascent Biotech Financials

NBIO

Source SEC Filings (10-K/10-Q) Updated Jun 30, 2024 Currency USD FYE March

This page shows Nascent Biotech (NBIO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NBIO FY2024 2026-04-22

Nascent Biotech’s cash position improved in FY2024, but the business still runs on external financing rather than operations.

FY2024’s cleaner balance sheet was financed, not earned: total liabilities fell from $1.55M to $809K. Cash rose to $372K because financing supplied $1.39M, while operating cash flow remained negative, so the liquidity rebound came from new capital rather than self-funding.

Short-term pressure remains the main balance-sheet constraint: current assets of $552K still trail current liabilities of $809K. Because essentially all reported assets are current, there is little asset cushion and almost no long-duration balance-sheet support behind those obligations.

The visible cost mix is more overhead-heavy than research-heavy: FY2024 R&D was only $111K versus SG&A of $404K. With shares outstanding rising from 111.3M in FY2022 to 170.6M in FY2024, more of the company’s recent effort appears tied to staying funded than expanding development activity.

Financial Health Signals

Financial Profile 18/100

Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Nascent Biotech's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Nascent Biotech carries a low D/E ratio of -3.15, meaning only $-3.15 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Nascent Biotech's current ratio of 0.68 is below the typical benchmark, resulting in a score of 8/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Piotroski F-Score Weak

2/9

Nascent Biotech passes 2 of 9 financial strength tests. 1 of 3 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.57x

For every $1 of reported earnings, Nascent Biotech generates $0.57 in operating cash flow (-$1.2M OCF vs -$2.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-5.8x

Nascent Biotech earns $-5.8 in operating income for every $1 of interest expense (-$2.2M vs $385K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$2.1M

Nascent Biotech reported -$2.1M in net income in fiscal year 2024.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$372K

YoY+116.1%

5Y CAGR+23.1%

10Y CAGR+12.6%

Nascent Biotech held $372K in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

171M

YoY+29.5%

5Y CAGR+39.2%

10Y CAGR+37.6%

Nascent Biotech had 171M shares outstanding in fiscal year 2024. This represents an increase of 29.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$111K

YoY-59.0%

5Y CAGR-15.3%

10Y CAGR-11.7%

Nascent Biotech invested $111K in research and development in fiscal year 2024. This represents a decrease of 59.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

NBIO Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	$0-100.0%	$1.0M+33.3%	$750K	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$111K-59.0%	$271K+37.0%	$197K-38.7%	$322K	N/A	$254K
SG&A Expenses	$404K-0.4%	$405K+6.8%	$379K+5.6%	$359K	N/A	$448K
Operating Income	-$2.2M	N/A	-$457K+67.4%	-$1.4M	N/A	N/A
Interest Expense	$385K	N/A	$48K-82.2%	$269K	N/A	$0
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$2.1M	N/A	-$470K+50.9%	-$959K	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$15K	N/A	$47K+66.6%	$28K+9.3%	$26K	N/A	$56K-26.2%	$76K
SG&A Expenses	$106K	N/A	$102K+24.3%	$82K-6.5%	$88K	N/A	$133K+62.1%	$82K
Operating Income	-$376K	N/A	-$364K+56.5%	-$837K	N/A	N/A	-$475K+8.9%	-$521K
Interest Expense	$2K	N/A	$107-99.9%	$125K-47.4%	$238K	N/A	$649K+135.2%	$276K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
Net Income	-$377K	N/A	-$205K+75.2%	-$829K	N/A	N/A	-$837K-474.6%	-$146K
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	$-0.01	N/A

NBIO Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$552K+116.5%	$255K+141.9%	$105K-86.0%	$751K+23251.0%	$3K-97.6%	$131K
Current Assets	$552K+116.5%	$255K+141.9%	$105K-86.0%	$751K+23251.0%	$3K-97.6%	$131K
Cash & Equivalents	$372K+116.1%	$172K+82.4%	$94K+6484.0%	$1K-55.4%	$3K-97.6%	$131K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	$0-100.0%	$750K	$0	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$809K-47.9%	$1.6M+99.7%	$777K-36.5%	$1.2M-57.5%	$2.9M+369.2%	$614K
Current Liabilities	$809K-47.9%	$1.6M+99.7%	$777K-36.5%	$1.2M-57.5%	$2.9M+369.2%	$614K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$257K+80.2%	-$1.3M-93.0%	-$671K-42.1%	-$473K+83.6%	-$2.9M-496.4%	-$482K
Retained Earnings	-$24.3M-12.2%	-$21.6M-14.9%	-$18.8M-2.6%	-$18.4M-9.0%	-$16.8M-31.2%	-$12.8M

Metric	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23
Total Assets	$227K-58.8%	$552K-13.9%	$641K-38.5%	$1.0M+1221.1%	$79K-69.1%	$255K-54.9%	$566K-52.9%	$1.2M
Current Assets	$227K-58.8%	$552K-14.0%	$642K-38.5%	$1.0M+1221.1%	$79K-69.1%	$255K-54.9%	$566K-52.9%	$1.2M
Cash & Equivalents	$47K-87.3%	$372K-40.4%	$624K-37.9%	$1.0M+10490.4%	$9K-94.5%	$172K-69.2%	$559K-52.7%	$1.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$742K-8.3%	$809K+32.4%	$611K-41.8%	$1.0M-12.1%	$1.2M-23.0%	$1.6M-19.6%	$1.9M-19.2%	$2.4M
Current Liabilities	$742K-8.3%	$809K+32.4%	$611K-41.8%	$1.0M-15.0%	$1.2M-20.4%	$1.6M-19.6%	$1.9M-19.2%	$2.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$515K-100.5%	-$257K-945.2%	$30K+573.7%	-$6K+99.4%	-$1.1M+14.0%	-$1.3M+5.0%	-$1.4M-14.8%	-$1.2M
Retained Earnings	-$24.6M-1.6%	-$24.3M-2.2%	-$23.7M-0.9%	-$23.5M-6.2%	-$22.2M-2.5%	-$21.6M-2.5%	-$21.1M-4.1%	-$20.3M

NBIO Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$1.2M	N/A	$413K+141.9%	-$987K	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$1.4M	N/A	-$321K-132.5%	$985K	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23
Operating Cash Flow	-$325K+7.7%	-$352K-6.5%	-$330K+3.3%	-$342K-109.9%	-$163K+57.9%	-$387K+38.0%	-$623K-43.7%	-$434K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	$100K+300.0%	-$50K-103.7%	$1.3M	$0	$0	$0-100.0%	$1.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NBIO Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	-45.7%+141.0pp	-186.7%	N/A	N/A
Net Margin	N/A	N/A	-47.0%+80.8pp	-127.8%	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-378.1%	N/A	-446.2%-318.6pp	-127.6%	N/A	N/A
Current Ratio	0.68+0.5	0.16+0.0	0.14-0.5	0.61+0.6	0.00-0.2	0.21
Debt-to-Equity	-3.15-2.0	-1.20-0.0	-1.16+1.4	-2.59-1.6	-1.00+0.3	-1.27
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	-676.4%	N/A	N/A	N/A	N/A	N/A
Return on Assets	-166.0%	N/A	-32.0%+47.5pp	-79.5%	N/A	N/A	-148.0%-135.8pp	-12.1%
Current Ratio	0.31-0.4	0.68-0.4	1.05+0.1	0.99+0.9	0.06-0.1	0.16-0.1	0.29-0.2	0.50
Debt-to-Equity	-1.44+1.7	-3.15-23.3	20.12+183.8	-163.66-162.6	-1.07+0.1	-1.20+0.2	-1.41+0.6	-2.01
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$257K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.68), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Mosaic Immunoengineering Inc CPMV

$5.3M

Restart Life NMLSF

$3.9M

Tron Group TGRP

$4.2M

Nymox Pharm NYMXF

$12.3M

Avenue Therapeutics Inc ATXI

$2.8M

Frequently Asked Questions

Is Nascent Biotech profitable?

No, Nascent Biotech (NBIO) reported a net income of -$2.1M in fiscal year 2024.

What is Nascent Biotech's operating cash flow?

Nascent Biotech (NBIO) generated -$1.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Nascent Biotech's total assets?

Nascent Biotech (NBIO) had $552K in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Nascent Biotech spend on research and development?

Nascent Biotech (NBIO) invested $111K in research and development during fiscal year 2024.

How many shares does Nascent Biotech have outstanding?

Nascent Biotech (NBIO) had 171M shares outstanding as of fiscal year 2024.

What is Nascent Biotech's current ratio?

Nascent Biotech (NBIO) had a current ratio of 0.68 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is Nascent Biotech's debt-to-equity ratio?

Nascent Biotech (NBIO) had a debt-to-equity ratio of -3.15 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Nascent Biotech's return on assets (ROA)?

Nascent Biotech (NBIO) had a return on assets of -378.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Nascent Biotech's cash runway?

Based on fiscal year 2024 data, Nascent Biotech (NBIO) had $372K in cash against an annual operating cash burn of $1.2M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Nascent Biotech's debt-to-equity ratio negative or unusual?

Nascent Biotech (NBIO) has negative shareholder equity of -$257K as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Nascent Biotech's Piotroski F-Score?

Nascent Biotech (NBIO) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Nascent Biotech's earnings high quality?

Nascent Biotech (NBIO) has an earnings quality ratio of 0.57x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Nascent Biotech cover its interest payments?

Nascent Biotech (NBIO) has an interest coverage ratio of -5.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Nascent Biotech?

Nascent Biotech (NBIO) scores 18 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.